PRP for Hair: Leukocyte-Rich vs Leukocyte-Poor Kits
Does leukocyte content matter when selecting a kit for scalp injection?
Leukocyte content is one of the few things about a preparation you actually control at the moment you choose a kit, so it deserves a real answer rather than a shrug. It's also not the thing that decides whether a scalp course works, and treating it as the headline variable pulls your attention away from platelet dose and injection depth, where the result is really won.
- Leukocyte-rich: Harvested deep into the buffy coat, white cells around three to five times baseline.
- Leukocyte-poor: Drawn above the buffy coat or after a second spin, white cells at or below baseline.
- Comparative scalp evidence: No direct head-to-head trials of the two categories in hair loss.
- Tolerability signal: Pooled joint injection data show more pain and swelling after leukocyte-rich preparations.
Leukocyte content is a real compositional choice with no head-to-head scalp evidence behind it, so total platelet dose, injection depth and session completion decide your result far more than white cell status does.
What does leukocyte content actually mean in a platelet concentrate, and how is it measured?
White cell content sounds like a single number until you go looking for the cut-off, and you'll find the field never agreed on one. What you can pin down is the direction of travel: leukocyte-poor sits at or below your patient's own baseline, leukocyte-rich runs three to five times above it, and the classification schemes exist to force out the detail a product name hides.
Leukocyte-poor means white cells at or below the patient's own baseline while buffy-coat harvesting devices measure around three to five times baseline, and expressing the result as a multiple of that individual baseline is the only figure that stays meaningful from one patient to the next.
How does a kit's separation design determine whether the final product is leukocyte rich or leukocyte poor?
Geometry decides this, not the label on the box. White cells settle into a narrow band right above the packed red cells, sitting on top of the densest platelet layer, so where your device is allowed to draw from is the whole ball game.
- Single soft spin, deep aspiration: You take the whole buffy coat, so you get a leukocyte-rich product.
- Double spin: The first spin removes red cells, the second concentrates platelets from the plasma, so you decant and resuspend without ever re-entering the buffy coat.
- Gel or buoy hardware: A separator gel or a density-matched float traps the red cells and much of the white cell layer beneath it.
- Spin force and duration: Higher g-force over longer runs packs the interface tightly, while a soft short spin leaves platelets and white cells mixed.
- The operator's own hand: On any open system pipetted to a visual landmark, two clinicians working the same tube produce different counts.
A kit's leukocyte profile is set by whether the harvest re-enters the buffy coat, which is why two-stage systems dominate the leukocyte-poor category and why excluding that layer costs platelet recovery from the same starting volume.
What does the clinical evidence on androgenetic alopecia say about leukocyte-rich versus leukocyte-poor preparations?
You want a clean verdict here and the literature can't hand you one, so the useful move is understanding why. Direct head-to-head trials of the two categories in pattern hair loss are essentially absent, and the pooled reviews that do exist split their subgroups by activation status or spin method instead of by white cells. Borrowing the orthopaedic answer is tempting, but a cycling follicle with its own immune privilege and resident macrophages isn't a cartilage surface.
| Criteria | Leukocyte-rich | Leukocyte-poor |
|---|---|---|
| Head-to-head scalp trials | None published | None published |
| Pooled density gain vs control | Reported, not split by leukocyte content | Reported, not split by leukocyte content |
| Post-injection pain and swelling | Significantly more common | Less common |
| Intra-articular preference | Generally avoided | Generally favoured |
Direct comparisons of leukocyte-rich and leukocyte-poor preparations in androgenetic alopecia are essentially absent from the published literature and no meta-analysis has isolated leukocyte content as a factor, which leaves the question untested rather than settled.
Which biological mechanisms make neutrophils and monocytes helpful or harmful around the hair follicle?
White cells aren't passive passengers, and the mechanistic case runs hard in both directions at once. Neutrophils turn up carrying proteases and reactive oxygen species, while the macrophages monocytes become are stitched into normal hair cycling. That's precisely why the biology can't arbitrate this and the clinical comparison has to.
- Neutrophil granules: Metalloproteinases, elastase and myeloperoxidase, plus reactive oxygen species once degranulated in tissue.
- Interleukin-1 beta: A documented inhibitor of hair shaft elongation in human follicle organ culture.
- Perifollicular macrophages: Influence the transition out of telogen and interact with bulge stem cells.
- Existing micro-inflammation: Many alopecia biopsies already show lymphocytic infiltrate and progressive perifollicular fibrosis.
White cells bring both catabolic activity through neutrophil proteases and interleukin-1 beta and genuine regulatory input through macrophages that govern telogen exit, so the mechanisms point in opposing directions and settle nothing on their own.
What patient-side reactions are more likely after a leukocyte-rich injection into the scalp?
This is where the leukocyte question actually turns up in your chair. Pooled data across injectable platelet therapy put significantly more injection-site pain and swelling after leukocyte-rich preparations, and a patient left sore for days after visit one is a patient who may never book visit three. Sort what's expected from what isn't before it happens, not after the phone call.
Pooled injectable platelet therapy data show significantly more injection-site pain and swelling after leukocyte-rich preparations, which threatens completion of a three or four session course more than it threatens safety, since actual infection stays rare with either product under sterile technique.
What specification details should a clinician check before assuming a kit's leukocyte profile?
Start from the position that the name on the box is a positioning decision, not a specification. Pure, advanced and leukocyte-optimised are unregulated descriptors, and two kits sold under the same word can differ several-fold in what reaches the syringe. Clearance won't close that gap for you, because it covers the device as a blood separator and certifies nothing about what's in the tube.
- White cell recovery: As a multiple of the patient's baseline, with the neutrophil fraction of it if that's disclosed at all.
- Platelet numbers, both of them: The concentration factor and the absolute platelet dose in the final volume.
- The draw those figures came from: A factor quoted against a large draw and a small output isn't comparable to one quoted the other way round.
- The validation behind the claim: Full data rather than a summary slide, how many donors it covered, and what the variability looked like.
- Which protocol was used: Many instructions document more than one spin or harvest option, and they don't deliver the same leukocyte profile.
Regulatory clearance covers a kit as a blood separation device and its safety in that role; it does not certify a composition claim, endorse a hair loss indication, or verify that white cell numbers match the brochure.
How much does leukocyte content matter compared with platelet dose, activation and injection technique?
Rank the levers honestly and leukocyte content lands mid-table, not at the top. If a cohort of your patients disappointed you, the audit order matters: dose first, then technique, then whether they finished the course, and only then the white cell profile of the kit.
Total platelet dose delivered to the treated area, injection depth and spacing, and completion of the full session course all outrank leukocyte content, which sits in the second tier alongside activation method.
Does the leukocyte question change the cost or repeat treatment calculus of choosing a kit?
The money here is smaller than the purchasing conversation implies, and it isn't sitting on the sticker price. Chair time and course completion are where the real difference shows up, and they pull against each other. Given how weak the comparative efficacy evidence is, nothing in the published record backs paying a substantial premium for a particular leukocyte profile.
| Cost line | Single-spin leukocyte-rich | Two-stage leukocyte-reducing |
|---|---|---|
| Consumable price per procedure | Usually lower | Often higher, small next to the session fee |
| Preparation time | One spin | Second cycle, decant and resuspension |
| Room and staff load | Clinician stays on schedule | Longer room use or a dedicated processor |
| Course completion | More soreness risks sessions three and four | Gentler experience supports the full course |
The consumable price gap between mainstream kits is usually a modest fraction of a single session fee, so an abandoned course costs a clinic far more than any leukocyte-related price difference, and a later switch adds retraining plus the loss of comparable outcome data.
